The NCI Radiation Oncology Branch and the NHLBI Laboratory of Single Molecule Biophysics seek parties to co-develop fluorescent nanodiamonds for use as in vivo and in vitro optical tracking probes toward commercialization.
NCI and NHLBI investigators invented a robust and easily implemented method of synthesizing silica-coated nanodiamonds for imaging and therapeutic applications. A patent estate covering these methods is offered for licensing to commercial entities. The method generally includes coating nanodiamonds with a silica precursor, e.g, tetraethylorthosilicate (TEOS), inside liposomes. The liposomes are then removed to yield a final product that is stable, monodisperse, and easy to functionalize.
- Drug delivery
- Small size
- Physiologically inert carrier
- Stable in aqueous solution
- Readily functionalized
- Biological activity is determined more efficiently than chemical analysis
- High Specificity and selectivity
Martin W Brechbiel (NCI), Keir C Neuman (NHLBI)
Yu SJ, et al. Bright fluorescent nanodiamonds: no photobleaching and low cytotoxicity. [PMID 16351080]
Wilson RM. Nanodiamonds are promising quantum probes of living cells. [DOI 10.1063/PT.3.1204]
Chow EK, et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. [PMID 21389265]
Krueger A. New carbon materials: biological applications of functionalized nanodiamond materials. [PMID 18033700]
- U.S. Patent Filed: U.S. Patent Application Number 61/672,996, Filed 18 Jul 2012
- U.S. Provisional: U.S. Provisional Patent Application Number 61/711,702, Filed 09 Oct 2012